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Abstract 
Purpose: Adipose tissue products may contribute to endometrial cancer (EC) initiation and further growth that 
encourages the analysis of this issue in patients with different obesity phenotypes.
Methods/patients: Omental fat depot characteristics were studied in EC patients (n = 57) with “standard” (SO) or 
“metabolically healthy” (MHO) obesity. Collected omental samples were evaluated by immunohistochemistry /IHC/ for 
brown fat marker UCP1, CYP19 (aromatase) and macrophage infiltration markers (CD68, CD163, crown-like structures/
CLS) expression. Total RNA extracted from the same samples was investigated for UCP1, CYP19, PTEN and adipokine 
omentin mRNA.
Results: Immunohistochemistry data revealed a statistically significant increase in aromatase and CD68 expression 
and tendency to increase of UCP1 expression in SO patients’ omental fat compared to samples obtained from MHO 
patients. Additionally, positive correlation of EC clinical stage with UCP1 protein and its mRNA content in omental fat 
was pronounced in MHO as well as SO group, while with omentin mRNA it was discovered only in patients with SO. 
An inclination to the correlation with better tumor differentiation was seen for UCP1 and CD68 protein expression in 
patients with MHO and with worse (high grade) differentiation—for CD68 expression in the group with SO.
Conclusions: In aggregate, this suggests that obesity phenotype has significant impact on omental fat tissue charac-
teristics which is related to the clinical course of EC and may have practical consequences.
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Background
Endometrial cancer (EC) is the most common gyneco-
logical cancer. Therefore, it has now long been a point 
of interest not only of oncologists and gynecologists, but 
also of specialists in other fields. One of most popular 
concepts of EC biology concerns its connections with 
obesity to which—especially in the last years—even a 
causal role has been rather often imputed [see (Byers and 
Sedjo 2015)]. Concerning an importance of this aspect, 
we should mention current tendencies, according to 
which by 2030 a roughly identical and noticeable (about 
50–60%) increase is expected in primary EC cases num-
ber (Sheikh et  al. 2014) as well as in obesity prevalence 
(Kelly et  al. 2008). Herewith, although for several dec-
ades a concept of obesity being primarily the predispos-
ing factor mainly for EC of type I dominated (Bokhman 
1983; Sherman 2000; Brinton et al. 2013), there are pres-
ently some new publications advocating no significant 
difference between type I and type II EC in this context 
(Setiawan et al. 2013).
Besides being the possible consequence of gradual 
changes in EC biology (Evans et al. 2011; Berstein et al. 
2015), the latter ascertaining may also be related to 
Open Access
*Correspondence:  levmb@endocrin.spb.ru 
1 Laboratory Oncoendocrinology, Pesochny, N.N.Petrov Research Institute 
of Oncology, Leningradskaya 68, St.Petersburg 197758, Russia
Full list of author information is available at the end of the article
Page 2 of 8Berstein et al. SpringerPlus  (2016) 5:1900 
another aspects of obesity problem and its study in uter-
ine body cancer patients. In particular, we must to stress 
that obesity and high body mass index are not equivalent 
entities (Crosbie et al. 2012) and that obesity draws atten-
tion not only due to the growing scale of its epidemics 
(Kelly et al. 2008), but also by the fact of its heterogene-
ity (Berstein 2012). Due to this, obesity is not always uni-
vocal in its manifestations and consequences, justifying 
in the first place the distinguishing between “standard” 
(SO), or insulin resistance-associated, and “metabolically 
healthy” (MHO) obesity phenotypes (Sims 2001; Karelis 
2008) and underlining the need in their comparative con-
sidering in cancer patients including patients with EC 
(Berstein et al. 2015; Berstein 2012; Calori et al. 2011).
It should be added that for determining of obesity role 
as an EC risk factor and its clinical course modifier (Brin-
ton et  al. 2013; Setiawan et  al. 2013; Fader et  al. 2009) 
an undeniable significance belongs to adipose tissue 
studies, where particular attention may attract a greater 
omentum fat depot located rather close to the uterus. 
Among other things, this corollary may be derived 
from uncoupling protein 1 (UCP1) research. While this 
mitochondrial protein is involved in thermogenesis and 
energy expenditure, finding of its mRNA in omental fat 
(Oberkofler et al. 1997) leads to conclusion that the lat-
ter can possess the properties of both, white and brown 
adipose tissue. Although functional roles of these tissues 
are supposed to be directly opposite in view of obesity 
prevention problem (Cypess and Kahn 2010), this con-
cept is not yet conventional (Jensen 2015) and needs fur-
ther elaboration [that is also true in regard of brown fat 
associations with cancer (Berstein 2012)]. On the other 
hand, the greater omentum fat depot belongs formally to 
visceral fat, which is supposed to be linked with insulin 
resistance and is capable to produce a set of adipokines 
(Ibrahim 2010), although the characteristics of these adi-
pokines vary significantly and some of them, in particular 
omentin, are mostly produced by stromal cells of adipose 
tissue (Yang et al. 2006).
In accordance with said above, our research was aimed 
at studying omental fat characteristics (in particular, 
expression of UCP1, omentin, aromatase/estrogen syn-
thetase, certain macrophage infiltration markers, etc.) 
in EC patients with “standard” (SO) and “metabolically 
healthy” (MHO) obesity and at evaluation of these char-
acteristics relation to cancer process features.
Methods and patients
A total of 57 treatment-naïve patients (mean age of 
60.1  years) mostly with early EC stages (43 with Ia-c, 9 
with IIa-b, 5 with IIIa-b) were enrolled. About two-
thirds of tumors were endometrioid adenocarcinomas. 
Besides EC stage and morphology, its differentiation 
grade (G-grade) was determined. In 2–3 days before sur-
gical intervention anthropometric values (body mass, 
height, body mass index/BMI/) were evaluated, and body 
fat content was determined by bioelectrical impedance 
test. At the same time point hormone-metabolic status 
of patients was assessed. It included evaluation of fast-
ing serum glucose, cholesterol and triglycerides values 
(Vector-Best kits, Novosibisk, Russia), as well as insulin 
(by ELISA kit of DRG, Germany) and omentin (ELISA kit 
of BioVendor, Chech Republic) serum values. The insu-
lin resistance index (HOMA-IR) value was calculated 
according to the formula: fasting insulin (μU/l) × fasting 
glucose (nmol/l)/22.5 (Matthews et al. 1985).
Patients were divided into groups according to BMI 
values:  <25.0, 25.0–29.9 and  ≥30.0. Among patients 
with BMI values of ≥25.0 the ones with clinical signs of 
MHO or SO were detected. The first group consisted of 
EC patients not having at least three of the following five 
criteria: impaired glucose tolerance/hyperinsulinemia, 
hypertriglyceridemia, waist circumference increase, low 
serum high-density cholesterol values and arterial hyper-
tension. These criteria were chosen in accordance with 
current guidelines (Samocha-Bonet et al. 2014).
Omental fat samples (not having signs of metastases 
and taken during surgical intervention approximately 
from the same inferior area of big omentum in practi-
cally all patients) were fixed in 10% formalin for further 
paraffin embedding and immunohistochemistry assay 
(n  =  50). Analogous samples (n  =  57) were instantly 
placed in liquid nitrogen and stored at −70 °C for further 
total RNA extraction. The immunohistochemical expres-
sion of mitochondrial UCP1 protein (polyclonal rabbit 
antibodies, Thermo Scientific; dilution 1:500), as well as 
aromatase (estrogen synthetase) (polyclonal rabbit anti-
bodies Abcam 65693, 1:50), macrophage markers CD68 
(polyclonal rabbit antibodies, Dako, 1:200) and CD163 
(monoclonal mouse antibodies, Novocastra, 1:100) was 
studied in deparaffinized sections of omental fat tissue. 
Additionally, the incidence of inflammation-associated 
macrophage infiltration markers known as crown-like 
structures (CLS), which consist of dead adipocytes sur-
rounded by macrophages (Bigornia et  al. 2012), was 
evaluated (see, please, examples of IHC images in Fig. 1). 
Quantitation was made by two independent experts 
(M.M., L.M.B), which took into account intensity of 
staining and average percent of stained cells per unit of 
the section square.
In the course of preparation to real-time PCR for UCP1, 
CYP19 (aromatase), omentin and PTEN genes mRNA 
expression evaluation a preliminary total RNA extraction 
from frozen omental fat tissue and complementary DNA 
(cDNA) analysis by reverse transcription reaction were 
performed. For this a 0.2 cm3 of fat were homogenized in 
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500 µl of TRIzol (Life Technologies), the lysate obtained 
was centrifuged at 12,000 rpm in +4 °C environment for 
10 min, then the hypophase was transferred to clean test 
tube. To each tube 150  µl of 24:1 chloroform and isoa-
myl alcohol mixture was added. The sample was mixed 
and centrifuged at 12,000 rpm in +4 °C environment for 
15 min and RNA-rich upper phase was collected. mRNA 
was precipitated by isopropyl alcohol in the presence of 
glycogen, rinsed by 70% ethanol and dissolved in water. 
Then, the RNA solution was diluted tenfold and used for 
complementary DNA (cDNA) synthesis in 20-µl reverse 
transcription reaction. The reaction mix included 10  µl 
of RNA solution, 10×  buffer for reverse transcriptase 
(2.0  µl), M-MulV reverse transcriptase (Sibenzyme) 
(150,000  IU/ml) (1.0  µl), dNTP mix (10  mM of each 
nucleotide) (1.0 dNTP), random hexaprimers (conc. of 10 
ODU/ml) (1.0 µl), and RNase inhibitor (5 IU/µl) (1.0 µl). 
The following temperature schedule of reverse transcrip-
tion was used: 20  °C for 5 min, 38  °C for 30 min, 95  °C 
for 5  min. The cDNA sequences target and reference 
gene (SDHA) were amplified with specific primers in the 
presence of TaqMan probes (Table 1). Real-time PCR was 
performed with BioRad CFX96 Real-time PCR Detec-
tion System equipment in N.N.Petrov Research Institute 
of Oncology molecular oncology laboratory. A 20-µl 
reaction mix contained 1 µl of cDNA solution, 2.0 units 
of active Thermostar DNA polymerase, onefold PCR 
buffer, 2.5 mM of MgCl2, 200 µM of each NTPs, 300 nM 
of direct and reverse primers, and TaqMan probe. The 
following PCR amplification conditions were used: 20  s 
of denaturation at 95  °C, annealing and synthesis for 
1 min at 60 °C, 45 cycles. The relative expression of each 
gene in samples was calculated by 2−∆Ct formula (where 
Ct means Cycle threshold, ∆Ct  =  Ct (target gene)—Ct 
(reference gene, SDHA, succinate dehydrogenase cata-
lytic subunit).
During statistical analysis parametric (Student’s t test) 
and—in samples without normal distribution—non-
parametric methods (mostly χ2 test, Pearson criterion 
and Fisher’s exact test with Yates correction) were used. 
Calculations were made with Statistica, v.10 and Sigma-
Plot software. The changes were considered statistically 
significant if p value was ≤0.05. The study of correla-
tions between omental fat state and tumor characteristics 
relied on Spearman’s correlation coefficient calculations. 
All patients included in the study signed a consent form, 
although the specific informed consent obtainment was 
not mandatory since personal data of individual patients 
were not presented. An approval of Local Ethics Com-
mittee was obtained for this study in accordance to the 
Fig. 1 Examples of IHC staining of omental fat in endometrial cancer patients a CD68 b CD163 c UCP1 d Aromatase e Corona-like structures (CLS). 
Magnification ×400
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principles formulated by the 1964 Helsinki declaration 
and its later amendments, which were strictly followed in 
the course of the investigation. All procedures performed 
in studies involving human participants were compatible 
with institutional and national research committees’ ethi-
cal standards.
Results
In the course of these studies, several directions in omen-
tal fat evaluation were exploited, in particular: (a) com-
parison of this tissue characteristics in patients with 
different BMI values and signs of SO or MHO obesity; (b) 
comparison of results in patients with endometrioid and 
non-endometrioid endometrial carcinomas; (c) estab-
lishing by correlation analysis the connection between 
expression of studied omental fat markers and cancer 
characteristics (clinical stage and differentiation grade).
According to immunohistochemistry data analy-
sis (Table  2) there were no distinctions in omental fat 
expression for any of the proteins studied (UCP1, aro-
matase, CD68 and CD163) between endometrioid and 
non-endometrioid uterine body cancer patients. Also, 
the same methodology did not yield evidence in favor 
of BMI increment correlation to changes in expres-
sion of aromatase/estrogen synthetase, markers of tis-
sue macrophage infiltration (CD68, CD163) as well as 
UCP1 (although latter parameter demonstrated a higher 
mean value in EC patients with normal/<25.0/BMI, this 
observation most probably could be explained by promi-
nent dispersion of individual values). However, when we 
switched from BMI values to obesity phenotypes, SO 
patients’ population demonstrated statistically significant 
increase in aromatase and macrophage marker CD68 
expression compared to MHO group. In SO group, there 
was also a tendency to higher UCP1 protein expression 
(Table  2). This latter result has been somewhat unex-
pected since UCP1 protein is responsible for heat gen-
eration in brown adipose tissue (along with uncoupling 
of the respiratory chain) and has several other functions 
(Oberkofler et al. 1997; Cannon et al. 2006), see “Discus-
sion” section.
Of note, in spite of above mentioned increase of CD68 
expression in omental fat of SO group, the expression of 
other proinflammatory marker, crown-like structures 
(CLS), in this tissue was the same for both SO and MHO 
patients (CLS were found in 19.4 and 18.2% of cases, 
respectively). However, according to available data (Bigor-
nia et al. 2012), CLS density of greater omentum fat tissue 
is much less pronounced compared to other visceral and 
subcutaneous fat tissue depots, and this probably makes 
the CD68 expression data obtained by us in patients with 
different obesity phenotypes (Table 2) more tenable.
In comparison to immunohistochemistry data analysis, 
the data on studied genes mRNA expression in omental 
fat tissue yielded only a tendency to increase in UCP1 
and (less so) omentin signal intensity in EC patients 
with BMI values >25.0. No difference in mRNA expres-
sion data was found in omental fat in relation to tumor 
morphology (endometrioid vs non-endometrioid) and 
obesity type. Although arithmetic mean mRNA values 
of studied samples seemed to be different, it was just an 
effect of the values distribution which was far from nor-
mal (or Gaussian) that could easily be proved by Fischer’s 
exact test and χ2 test results (Table 3).
Table 1 Primer sequences used for studied genes mRNA expression assay
UCP1 uncoupling protein one, CYP19A1 cytochrome 19, aromatase, PTEN phosphatase and tension homolog, SDHA succinate dehydrogenase catalytic subunit










PTEN ex 5/6-F GAGACAAAAAGGGAGTAACTAT 155
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On the other hand, according to the rank correla-
tion analysis UCP1 expression in omental fat was more 
pronounced in patients with advanced clinical stages of 
EC, and this was more evident in MHO group (Table 4). 
Omentin mRNA expression in omental fat depot dem-
onstrated a modest tendency to positive correlation with 
EC stage in SO group, although fat tissue omentin mRNA 
level correlated to its serum values only in patients with 
MHO (correlation coefficient ρ  =  0.44), but not in SO 
patients (ρ =  0.05). In addition, an inclination to corre-
lation between expression levels in omental adipose tis-
sue and better tumor differentiation (G1) was found for 
UCP1 and CD68 protein in patients with MHO and with 
worse (high grade, G3) differentiation—for UCP1 mRNA 
(in MHO group) and CD68 protein expression (in SO 
group) (Table 4).
Discussion
In endometrial cancer patients the omental fat depot 
can be considered from at least two points of view: as 
an important region for metastatic spread [even on rela-
tively early cancer stages (Joo et al. 2015)] and as a source 
of hormone-like and pro-inflammatory regulatory signals 
able to influence endometrial carcinogenesis and tumor 
progression (Klopp et  al. 2012). The second of these 
“characteristics” is as yet much less studied (Klopp et al. 
Table 2 Expression of studied proteins in omental fat of endometrial cancer patients with different body mass index val-
ues and obesity phenotypes (immunohistochemistry)
Notes: The immunohistochemistry staining evaluation was based on a score system (result/score): (−) 0, (±) 0.5, (+) 1, (++) 2, (+++) 3, (++++) 4; BMI body mass 
index, SO “standard” obesity, MHO “metabolically healthy” obesity. Aromatase—estrogen synthetase; UCP1—an “uncoupling” protein involved in thermogenesis; 
CD68—a marker mostly expressed by macrophages (predominantly M1 type), including macrophages infiltrating fat tissue; CD163–M2 type macrophages marker 
[see (Bigornia et al. 2012) and “Discussion” section]. p (1) < 0.1; p (2, 3, 4) < 0.05. Number in brackets is the number of cases
Group Expression score for proteins studied (M ± m) BMI (M ± m)
UCP1 Aromatase CD68 CD163
BMI <25.0 (8) 0.71 ± 0.41 0.81 ± 0.28 1.31 ± 0.28 2.00 ± 0.27 22.68 ± 0.46
BMI 25.0–29.9 (14) 0.46 ± 0.17 0.71 ± 0.16 0.79 ± 0.20 2.00 ± 0.21 28.63 ± 0.27
BMI ≥30.0 (28) 0.39 ± 0.10 0.88 ± 0.28 1.22 ± 0.19 2.43 ± 0.12 36.09 ± 1.05
SO (31) 0.48 ± 0.111 0.93 ± 0.122 1.26 ± 0.183 2.39 ± 0.13 34.84 ± 1.104
MHO (11) 0.23 ± 0.101 0.50 ± 0.172 0.60 ± 0.213 2.00 ± 0.19 30.11 ± 0.804
Endometrioid carcinomas (37) 0.49 ± 0.12 0.77 ± 0.11 1.00 ± 0.12 2.17 ± 0.12 32.45 ± 1.23
Non-endometrioid carcinomas (13) 0.41 ± 0.11 1.05 ± 0.22 1.27 ± 0.31 2.38 ± 0.21 30.00 ± 1.21
Table 3 mRNA expression of studied genes in omental adipose tissue samples from endometrial cancer patients with dif-
ferent body mass index and obesity phenotype (real-time PCR)
A relative expression of each gene in samples was calculated using a 2−∆Ct formula (where Ct is cycle threshold), ∆Ct = Ct (target gene)—Ct (reference gene, SDHA, 
see “Methods and patients” section). Each of subgroups lacked an expression in some samples; mean values are given for cases with gene expression
BMI body mass index, SO “standard” obesity, MHO “metabolically healthy” obesity. Numbers of cases are presented in brackets. UCP1—see notes to Table 2. CYP19 
cytochrome 19, aromatase; Omentin—adipokine (fat tissue hormone initially discovered in a great omentum depot, see “Discussion” section); PTEN phosphatase 
(Phosphatase and tensin homolog) gene, whose mutation or lowered expression quite often is found in malignant tumors, including endometrial cancer (see 
“Discussion” section)
Student’s t-test: p1 0.05; p2 0.06. Fischer’s exact test (by number of cases ≥ median for the whole group): I p 0.53; II p 0.50; III p 0.073 (in favor of non-endometrioid 
tumors due to one extremely different value in endometrioid carcinomas group); IY p 0.32 (Chi-square p 0.39); Y p 0.59
Group mRNA expression value in units, 2−∆Ct (M ± m) BMI (M ± m)
UCP1 CYP19 Omentin PTEN
BMI <25.0 (9) 0.005 ± 0.0021 0.005 ± 0.002 0.383 ± 0.1522 1.029 ± 0.620IY 22.99 ± 0.38
BMI 25.0–29.9 (16) 0.022 ± 0.0081, I 0.008 ± 0.002 1.268 ± 0.476 3.400 ± 1.540 28.54 ± 0.26
BMI ≥30.0 (32) 0.919 ± 0.900I 0.010 ± 0.003 0.752 ± 0.318 4.920 ± 3.372 36.41 ± 1.11
BMI ≥25.0 (48) 0.932 ± 0.2652 4.473 ± 2.269IY
SO (33) 0.019 ± 0.006II 0.007 ± 0.001 0.843 ± 0.300 4.242 ± 3.220 34.62 ± 1.11
MHO (14) 1.642 ± 1.620II 0.015 ± 0.007 1.161 ± 0.564 4.629 ± 1.780 31.65 ± 1.54
Endometrioid carcinomas (41) 0.592 ± 0.579III 0.008 ± 0.003 0.802 ± 0.284 2.208 ± 0.807Y 32.76 ± 1.13
Non-endometrioid carcinomas (14) 0.030 ± 0.013III 0.010 ± 0.002 0.960 ± 0.394 7.569 ± 5.885Y 29.61 ± 1.62
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2012; Zemlyak et al. 2012). However, considering the role 
of excessive fat mass as an EC risk factor (Bokhman 1983; 
Sherman 2000; Brinton et al. 2013; Setiawan et al. 2013; 
Fader et  al. 2009) and the fact of obesity heterogeneity 
(Berstein 2012), the research of omental fat features in 
EC patients is undoubtedly important at least since this 
fat tissue depot is located nearby from the uterus.
Here we should mention several factors, which were 
also the stimulus for us to conduct this research. F.e., 
no studies of this kind had been made which took into 
account different phenotypes of obesity. Further, accord-
ing to some data [in particular, a comparative data on 
omental and subcutaneous fat tissue UCP1 expression 
(Esterbauer et al. 1998)], the greater omentum fat depot 
may have brown as well as white fat tissue properties. 
Multilocular adipocytes, which are characteristic for 
brown fat tissue, are found though in omental fat only in 
very special situations (Frontini et  al. 2013). Neverthe-
less, the supposed plasticity or trans differentiation of 
adipocytes and their predecessors [allowing also white 
fat tissue cells acquire some brown fat cells characteris-
tics (Smorlesi et al. 2012)] draws additional attention to 
omental fat functional abilities, which determine whether 
it is closer to white or brown fat tissue in postmenopausal 
EC patients. Therefore, this was another reason for inter-
est in fat tissue markers (especially UCP1 and omentin) 
expression comparison in EC patients with “standard” 
and “metabolically healthy” obesity.
There are some notable and previously undescribed 
aspects of this research, which constitute its strengths. 
First, while omental fat tissue immunohistochemistry 
data analysis did not reveal connection between studied 
characteristics and body mass index or EC morphology, 
the fat tissue depot samples obtained from patients with 
MHO were characterized by lower—than in SO group—
aromatase (estrogen synthetase) and pro-inflammatory 
macrophage marker CD68 expression. There was also 
a tendency to lower UCP1 expression in patients with 
MHO (Table 2).
The mRNA expression was also studied, although this 
data (on the basis its mean values) turned out to be less 
informative. It confirmed IHC data on the absence of dis-
tinctions in omental fat characteristics between patients 
with endometrioid and non-endometrioid carcinomas, 
while yielded no differences between SO and MHO 
groups (Table  3) in spite of just mentioned distinctions 
discovered by immunohistochemistry assay. In particular, 
mRNA data did not demonstrate in these groups any dif-
ference in expression of aromatase (estrogen synthetase) 
and PTEN genes (Table 2). The latter is a tumor suppres-
sor gene subject to negative regulation by Akt/PKB sign-
aling pathway (Tokunaga et  al. 2008). Although PTEN 
is undoubtedly involved in EC carcinogenesis (Sherman 
2000; Feng et  al. 2012), there is only scarce data on its 
tumor expression in obese EC patients [see (Westin et al. 
2015)] and no publications describing PTEN expression 
in adipose tissue of obese/non-obese patients with EC.
One of the conclusions from our results (showing in 
this case the greater practical value of immunohisto-
chemistry compared to mRNA expression study, see 
Tables 2 and 3) is a necessity of studying omental fat sam-
ples in EC patients not only for PTEN gene, but also for 
its protein expression. The same conclusion can be made 
in regard of omentin IHC studies advisability, since—as 
had been discovered by us—a connection between this 
adipokine mRNA expression in omental fat and clinical-
morphological EC features was rather modest (Table 4). 
Of note, in EC patients’ population we could not find any 
association between serum omentin concentration or its 
mRNA expression in omental tissue samples and BMI 
value (data not presented) in spite of published evidence 
of negative correlation between serum omentin level and 
Table 4 Spearman rank correlation of omental fat markers expression with tumor characteristics in endometrial cancer 
patients with ‘standard’ (SO) or ‘metabolically healthy’ (MHO) obesity
See the “Methods and patients” section and notes to the Tables 2 and 3 for data evaluation methods explanation
In brackets: number of studied patients (samples)
Group Immunohistochemistry, proteins mRNA (correction by reference gene)
UCP1 Arom CD68 CD163 UCP1 Arom (CYP19) omentin PTEN
SO
 Differentiation (G) −0.006 (30) 0.063 (29) 0.277 (25) 0.158 (31) −0.294 (21) 0.224 (24) 0.168 (30) −0.174 (22)
 Clinical stage 0.227 −0.113 −0.091 0.172 0.303 0.010 0.253 −0.170
MHO
 Differentiation (G) −0.401 (11) 0.040 (10) −0.262 (10) 0.026 (11) 0.365 (11) −0.071 (11) −0.179 (12) 0.000 (12)
 Clinical stage 0.596 0.255 0.0392 −0.099 0.786 −0.170 0.111 −0.123
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excessive body mass (Tan et al. 2008) [although there is 
also a report stating the contrary (Choi et al. 2011)]. One 
also should not forget that while omentin is commonly 
viewed as a typical visceral adipokine, it (as already men-
tioned in Introduction) is mostly produced by fat tis-
sue stromal cells but not adipocytes (Yang et  al. 2006). 
Its serum values vary up and down in different cancer 
patients populations (Uyeturk et  al. 2014; Shen et  al. 
2016), although so far no data on this subject was pre-
sented in regard of EC patients.
Also, as the analysis of immunohistochemistry and 
mRNA expression data in omental depot of patients 
with endometrioid and non-endometrioid cancer found 
no evident difference [indirectly confirming recent data 
which did not demonstrate significant distinctions in 
obesity prevalence between patients with EC type I or II 
(Setiawan et al. 2013)], it may be an additional argument 
to consider obesity phenotype as a deserving attention 
factor able to influence omental fat tissue characteristics 
in the capacity of potential endometrial carcinoma clin-
ical course modifier. Indeed, we managed to find a posi-
tive correlation between UCP1 expression on protein as 
well as mRNA level in omental fat and endometrial can-
cer clinical stage. The correlation for UCP1 with clinical 
stage was stronger in “metabolically healthy” patients 
than in females with “standard” obesity (Table 4). There-
fore, although “metabolically healthy” obesity phe-
notype supposedly could be characterized by higher 
brown fat contents (Berstein 2012), UCP1 in this case 
looks rather like a marker of more “problastomogenic” 
visceral fat tissue, for which the omentum serves as one 
of depots.
There are several arguments in favor of this suggestion. 
First, the co-cultivation of omental adipose stromal cells 
(ASC) with endometrial cancer cell line Hec1a stimulates 
cell proliferation in a greater degree than co-cultivation 
with subcutaneous fat ASCs (Klopp et al. 2012). In addi-
tion, the UCP1 hyperexpression by tumor-associated 
stromal fibroblasts may potentiate cancer growth by 
providing high-energy nutrients in a paracrine fashion 
(Sanchez-Alvarez et  al. 2013). On the other hand, these 
are certainly not final and only arguments as, for exam-
ple, there is also data on exactly opposed (antitumor like) 
influence exerted by UCP1 (Chen et  al. 2009). Besides, 
the fact of positive correlation between UCP1 expres-
sion level in omental fat and EC clinical stage, which is 
more evident—as was just mentioned—in MHO patients, 
cannot abolish our earlier data, according to which 
endometrial cancer clinical stage is more advanced in 
patients with “standard” (insulin resistance-associated) 
obesity (Berstein et al. 2015). In addition to this, among 
other studied markers as rather logical seem opposite 
associations of macrophage lineage label CD68 with 
EC differentiation grade (low and high, respectively) in 
females with MHO and SO (Table 4).
In summary, the EC patients omental fat tissue depot 
characteristics are influenced by obesity phenotype of 
the patient and have a certain correlation with tumor fea-
tures. These observations can be—among other mecha-
nisms related to adipocytes themselves—explained, in 
particular, by effect of some mediating factors associated 
with macrophage infiltration (Tables 2, 4) or so-called adi-
pose inflammation (Howe et al. 2013; Linkov et al. 2014). 
These assumptions need further investigation of omental 
fat in different obesity phenotypes, especially in context 
of potential preventive or therapeutic interventions. Pre-
sented data are not likely to be contested by certain limi-
tations of this study (in particular, the already mentioned 
fact of certain omental fat tissue markers, e.g. omentin, 
being studied only on mRNA, but not protein expres-
sion level). An expanding signs of EC molecular diversity 
[see f.e. data on POLE gene mutations analysis (Cancer 
Genome Atlas Research Network et al. 2013; Murali et al. 
2014)] is also ‘an item’ to be considered during analysis of 
obesity connection with risk factors, as well as with clini-
cal and morphologic features of EC. This fast accumulat-
ing evidence attracts additional attention to functional 
state of white and brown fat tissue in patients with dif-
ferent (and growing in number) EC types with the aim to 
compose useful practical recommendations.
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